Philipp Melhorn

11PUBLICATIONS
5CO-AUTHORS
Predictive and prognostic markersMolecular targetsEpigenetics (incl. genome methylation and epigenomics)Neurology and neuromuscular diseasesSolid tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jul 06, 2026
Oligometastatic neuroendocrine tumors: characteristics and prognosis.

|Jun 02, 2026
B7-H3 (CD276) as a candidate therapeutic target in medullary thyroid cancer.

|Jun 20, 2025
Comparisons of treatment performance and therapy sequences in neuroendocrine neoplasms using progression-free survival ratios.

Philipp Melhorn, Elisabeth Kretschmer-Chott, Peter Mazal

|Mar 12, 2025
Methylation Profiles Differ According to Clinical Characteristics in Well-Differentiated Neuroendocrine Tumors of the Lung.

Philipp Melhorn, Erwin Tomasich, Alissa Blessing

|Oct 15, 2024
Liver metastases in high-grade neuroendocrine neoplasms: A comparative study of hepatic tumor volume and biochemical findings in NET G3 versus NEC.

Philipp Melhorn, Markus Raderer, Peter Mazal

|Sep 24, 2024
Long-term experience with octreotide and lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors.

Barbara Kiesewetter, Friedrich Franz Pflüger, Philipp Melhorn

Pageof 2

Frequent Collaborators

10 joint publications

Barbara Kiesewetter

4 joint publications

Markus Raderer

1 joint publications

Anna Sophie Berghoff

1 joint publications

Matthias Preusser